SynthesisPediatric cardiology2026
Optimal Strategy for Thromboprophylaxis in Fontan Circulation: A Systematic Review and Meta-analysis with a Focus on Ethnic Differences.
Synthesis in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Fontan circulation alters cardiovascular hemodynamics to maintain circulation using a single ventricle, which may consequently increase the risk of thromboembolism. This highlights the need for effective thromboprophylaxis strategies. This study assessed optimal thromboprophylaxis regimens for patients with Fontan circulation through a comprehensive meta-analysis of literature focused on personalized, ethnicity-based approaches. PubMed, Embase, and Cochrane Library databases were searched to identify studies reporting the thromboembolic and bleeding outcomes of patients with Fontan circulation. Thirty reports-four randomized controlled trials and 26 cohort studies-were analyzed. Aspirin (risk ratio [RR], 0.46; 95% confidence interval [CI], 0.2-1.08; p = 0.07), warfarin (RR, 0.40; 95% CI, 0.24-0.65; p < 0.001), and direct oral anticoagulants (DOACs) (RR, 0.22; 95% CI, 0.01-7.57; p = 0.4) were compared with no antithrombotic therapy, and only warfarin use resulted in a statistically significant reduction in thromboembolic risk, whereas the effects of aspirin and DOACs were not statistically significant. In the East Asian subgroup, aspirin significantly decreased thromboembolic risk, compared with no intervention (RR, 0.31; 95% CI, 0.16-0.58; p < 0.001), and was significantly more effective than warfarin (RR, 0.57; 95% CI, 0.37-0.88; p = 0.01). Bleeding risk showed no significant between-group differences. Compared with no intervention, thromboprophylaxis in patients with Fontan circulation reduces thromboembolic risk. Although our findings should be carefully interpreted because of the limited data, they indicate that aspirin may be more effective than warfarin in East Asian patients, underscoring the need for further research into ethnicity-tailored thromboprophylaxis strategies.
Indexed as
Identifiers
41071335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.